Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
146.00    0.00 (0.00%)
Bid:
145.00
Ask:
147.00
Spread: 2.00 (1.379%)
Market Cap: £123.56m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Senior Management Appointments

11 Jul 2024 07:00

RNS Number : 9478V
Diaceutics PLC
11 July 2024
 

Diaceutics Makes Four Senior Management Appointments

VP Chief of Staff, VP of Human Resources, VP of Engagement Solutions and VP of Real-World Data

New roles will further strengthen management team and drive continued innovation, performance & growth at Diaceutics

 

Belfast and London, 11 July 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce four appointments to its executive team. These appointments are part of Diaceutics' commitment to strong governance and ensuring it has the structure in place to capitalise upon the growth in its market. The new Vice Presidents - Madeline Brown, Norma Thompson, Gosia Leitch, and Scott Phillips - bring a wealth of experience and expertise to their respective roles and will add significant strength to Diaceutics' leadership team and as it drives continued innovation, performance and growth.

Diaceutics CEO Ryan Keeling said, "Madeline, Norma, Gosia, and Scott are dynamic leaders whose extensive experience, vision and innovative approaches will be crucial in shaping Diaceutics' future performance and growth. As we continue to expand, their perspectives will be essential to helping us reach our full potential."

Madeline Brown, VP, Chief of Staff

Madeline Brown has been with Diaceutics since 2007, holding significant roles in finance and strategic project management. She will now lead the Chief Executive's Office, focusing on driving efficiencies and scalability.

Norma Thompson, VP of Human Resources

Norma Thompson joined Diaceutics in 2019 as Global Head of Human Resources. With over 30 years of experience, she brings extensive knowledge in HR management, talent development, and regulatory environments, essential for Diaceutics' global operations.

Gosia Leitch, VP of Engagement Solutions

Gosia Leitch has over 20 years of experience in diagnostics and pharma, including roles at Veracyte, Abbott, Qiagen, Bayer Healthcare and SC Johnson. She will drive engagement strategies connecting diagnostics with the broader healthcare ecosystem.

Scott Phillips, VP of Real-World Data

Scott Phillips brings over 12 years of experience in real-world data, product development, strategy consulting, and business development. Previously at Komodo Health and COTA Healthcare, he will enhance Diaceutics' data strategy and integration of real-world evidence.

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Enquiries:

Diaceutics PLC 

Ryan Keeling, Chief Executive Officer

Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison, Nick Harland, Kate Hanshaw 

Alma Strategic Communications

Tel: +44(0)20 3405 0205 

Caroline Forde, Kinvara Verdon, Kieran Breheny

diaceutics@almastrategic.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADZGMNRGDGDZM
Date   Source Headline
27th Feb 20247:00 amRNSExpanded lab network and data capabilities
14th Feb 20241:00 pmRNSDiaceutics PLC - Strategic alliance with KPMG
5th Feb 20247:00 amRNSAppointment of VP, Scientific & Medical Services
1st Feb 202412:31 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
30th Jan 20247:00 amRNSDiaceutics PLC – Trading Update
25th Jan 20241:16 pmRNSExercise of Warrant & Total Voting Rights
19th Jan 20247:00 amRNSDiaceutics PLC – Financial Calendar Update
29th Dec 20231:18 pmRNSPDMR Shareholding/Share Incentive Plan
30th Nov 202312:59 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
30th Nov 20237:00 amRNSDiaceutics to attend Stifel Conference in NYC
21st Nov 202311:13 amRNSNotification of Major Holdings
31st Oct 202312:38 pmRNSPDMR Shareholding/SIP & Total Voting Rights
11th Oct 20231:47 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
2nd Oct 20233:59 pmRNSBlock Listing Application to AIM
29th Sep 202311:19 amRNSHolding(s) in Company
26th Sep 20237:00 amRNSDiaceutics PLC – Half Year Results
26th Sep 20237:00 amRNSDiaceutics PLC - Planned CEO Transition
21st Sep 20232:37 pmRNSDiaceutics PLC – Directorate Changes
7th Sep 20237:00 amRNSAttending 10th Annual HealthTech Investment Forum
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
30th Aug 20232:56 pmRNSPDMR Shareholding/Share Incentive Plan
29th Aug 20237:00 amRNSDiaceutics launches daily alerts for DXRX platform
4th Aug 20237:00 amRNSCanaccord Genuity 43rd Annual Growth Conference
31st Jul 20233:19 pmRNSPDMR Shareholding/Share Incentive Plan
25th Jul 20237:00 amRNSTrading Update and Notice of Results
29th Jun 202312:07 pmRNSPDMR Shareholding/Share Incentive Plan
6th Jun 20237:00 amRNSPurchase and Sale of Shares and PDMR Shareholdings
5th Jun 20237:00 amRNSUSD 10.1 million multi-year enterprise engagement
31st May 20235:13 pmRNSPDMR Shareholding/Share Incentive Plan
19th May 202310:16 amRNSIssue of Share Options/PDMR Shareholdings
18th May 202311:46 amRNSResults of Annual General Meeting
11th May 20236:22 pmRNSPDMR Shareholdings
4th May 202310:34 amRNSPDMR shareholdings
28th Apr 20236:03 pmRNSPDMR Shareholding/Share Incentive Plan
26th Apr 20235:03 pmRNSPDMR Shareholding
25th Apr 20235:45 pmRNSNotice of AGM and Posting of Annual Report
17th Apr 20237:00 amRNSFinal Results
3rd Apr 20232:43 pmRNSPDMR Shareholding / Share Incentive Plan
20th Mar 20237:00 amRNSNotice of Results and Presentations
13th Mar 202310:15 amRNSRestoration - Diaceutics PLC
13th Mar 202310:12 amRNSFurther update regarding Silicon Valley Bank
13th Mar 20237:30 amRNSSuspension - Diaceutics PLC
13th Mar 20237:00 amRNSUpdate regarding Silicon Valley Bank
1st Mar 20231:57 pmRNSPDMR Shareholding/Share Incentive Plan
30th Jan 20235:11 pmRNSPDMR Shareholding/Share Incentive Plan
26th Jan 20237:00 amRNSUSD 7m enterprise engagements for data services
26th Jan 20237:00 amRNSTrading Statement and Strategy Update
3rd Jan 20237:00 amRNSPDMR Shareholding/Share Incentive Plan
29th Nov 20227:00 amRNSChange of Auditor
29th Nov 20227:00 amRNSPDMR Shareholding/Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.